Nitsche, Mirko

[["dc.bibliographiccitation.firstpage","195"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","202"],["dc.bibliographiccitation.volume","183"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Fest, Jan"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Gruendker, Carsten"],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Schmidberger, Heinz"],["dc.date.accessioned","2018-11-07T11:03:57Z"],["dc.date.available","2018-11-07T11:03:57Z"],["dc.date.issued","2007"],["dc.description.abstract","Background and Purpose: Simultaneous radiotherapy with chemotherapy is a standard treatment for inoperable non-small cell lung cancer (NSCLC), but the clinical outcome still remains poor. To further intensify treatment, substances need to be identified, which increase the effect of radiation on tumor cells without further enhancing toxicity to normal tissue. Hormones have a different toxicity profile than radiation or cytostatic drugs. As NSCLC often express estrogen receptors (ERs), the combination of genistein or estradiol and radiation in vitro was investigated. Material and Methods: A549 NSCLC cells with an inducible expression of a mutated TP53 and fibroblasts of a male donor (DF-18) were examined. ER expression was immunocytologically confirmed in all studied cell lines. Clonogenic survival was measured after incubation of the cells with genistein or estradiol (0.01 mu M and 10 mu M as maximum clinically applicable dose) and irradiation with different doses (0-4 Gy). The differentiation state of fibroblasts after combined therapy was analyzed. Results: A549 cells expressing mutated TP53 were more radioresistant than TP53 wild-type cells. Incubation of nonfunctional TP53 cells with genistein or estradiol increased radiosensitivity in both tested concentrations. By contrast, radiosensitivity of A549 with wild-type TP53 and DF-18 was not altered by hormonal incubation. In DF-18 radiation induced growth arrest that was not increased by additional hormonal incubation. Conclusion: NSCLC cells with nonfunctional TP53 might be sensitized against radiation by genistein or estradiol. As genistein is better tolerable than estradiol in patients, additional studies are warranted to assess potential gains of this combination therapy."],["dc.identifier.doi","10.1007/s00066-007-1561-0"],["dc.identifier.isi","000245452600006"],["dc.identifier.pmid","17406801"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51725"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","0179-7158"],["dc.title","Radiosensitization dependent on p53 function in bronchial carcinoma cells by the isoflavone genistein and estradiol in vitro"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","31"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","31"],["dc.bibliographiccitation.journal","Radiation Oncology"],["dc.bibliographiccitation.lastpage","10"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Schwarten, Dag"],["dc.contributor.author","Fister, Stefanie"],["dc.contributor.author","Grundker, Carsten"],["dc.contributor.author","Rave-Frank, Margret"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T10:59:33Z"],["dc.date.available","2018-11-07T10:59:33Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: Oncological results of radiotherapy for locally advanced prostate cancer (PC) are significantly improved by simultaneous application of LHRH analoga (e. g. goserelin). As 85% of PC express LHRH receptors, we investigated the interaction of goserelin incubation with radiotherapy under androgen-deprived conditions in vitro. Methods: LNCaP and PC-3 cells were stained for LHRH receptors. Downstream the LHRH receptor, changes in protein expression of c-fos, phosphorylated p38 and phosphorylated ERK1/2 were analyzed by means of Western blotting after incubation with goserelin and irradiation with 4 Gy. Both cell lines were incubated with different concentrations of goserelin in hormone-free medium. 12 h later cells were irradiated (0 - 4 Gy) and after 12 h goserelin was withdrawn. Endpoints were clonogenic survival and cell viability (12 h, 36 h and 60 h after irradiation). Results: Both tested cell lines expressed LHRH-receptors. Changes in protein expression demonstrated the functional activity of goserelin in the tested cell lines. Neither in LNCaP nor in PC-3 any significant effects of additional goserelin incubation on clonogenic survival or cell viability for all tested concentrations in comparison to radiation alone were seen. Conclusion: The clinically observed increase in tumor control after combination of goserelin with radiotherapy in PC cannot be attributed to an increase in radiosensitivity of PC cells by goserelin in vitro."],["dc.description.sponsorship","Deutsche Krebshilfe [106240]"],["dc.format.mimetype","application/pdf"],["dc.identifier.doi","10.1186/1748-717X-2-31"],["dc.identifier.fs","119077"],["dc.identifier.isi","000260343200001"],["dc.identifier.pmid","17718927"],["dc.identifier.ppn","559810636"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4370"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50728"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1748-717X"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","616"],["dc.title","No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro"],["dc.title.subtitle","Research"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1067"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","1074"],["dc.bibliographiccitation.volume","65"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Florez, Rodrigo"],["dc.contributor.author","Kahler, Elke"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Steiner, Wolfgang"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T09:32:05Z"],["dc.date.available","2018-11-07T09:32:05Z"],["dc.date.issued","2006"],["dc.description.abstract","Purpose: The aim of this study was to evaluate the efficacy of adjuvant radiotherapy after transoral laser microsurgery for advanced recurrent head-and-neck squamous cell carcinoma (HNSCC). Patients and Methods: Between 1988 and 2000, 37 patients with advanced local recurrences (23 local and 14 locoregional recurrences) of HNSCC without distant metastases were treated in curative intent with organ-preserving transoral laser microsurgery and adjuvant radiotherapy (before 1994 split-course radiotherapy with carboplatinum, after 1994 conventional radiotherapy). Initial therapy of the primary (8.1% oral cavity, 35.1% oropharynx, 13.5% hypopharynx, and 43.3% larynx) before relapse was organ-preserving transoral laser microsurgery without any adjuvant therapy. Results: After a median follow-up of 124 months, the 5-year overall survival rate was 21.3%, the loco-regional control rate 48.3%, respectively. In multivariate analysis, stage of original primary tumor (Stage I/II vs. Stage III/IV), and patient age (< 58 years vs. >= 58 years) showed statistically significant impact on prognosis. In laryngeal cancer, larynx preservation rate after treatment for recurrent tumor was 50% during follow-up. Conclusion: Our data show that organ-preserving transoral laser microsurgery followed by adjuvant radiotherapy is a curative option for patients who have advanced recurrence after transoral laser surgery and is an alternative to radical treatment. (c) 2006 Elsevier Inc."],["dc.identifier.doi","10.1016/j.ijrobp.2006.03.007"],["dc.identifier.isi","000238878800015"],["dc.identifier.pmid","16750331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31668"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0360-3016"],["dc.title","Long-term follow-up after transoral laser microsurgery and adjuvant radiotherapy for advanced recurrent squamous cell carcinoma of the head and neck"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]